Medicine

Statement from the Chief Public Health Officer of Canada on May 15, 2021

Saturday, May 15, 2021 - 6:00pm

For students in particular, this has been a difficult and stressful school year for many, adapting to uncertainty and changes.

Key Points: 
  • For students in particular, this has been a difficult and stressful school year for many, adapting to uncertainty and changes.
  • If you are struggling or having a difficult time know that there are options for resources and supports to help.
  • At the same time, the Public Health Agency of Canada is providing Canadians with regular updates on COVID-19 vaccines administered , vaccination coverage and ongoing monitoring of vaccine safety across the country.
  • Working together, Health Canada , the Public Health Agency of Canada , the National Advisory Committee on Immunization , Canada's Chief Medical Officers of Health and other health professionals across the country are closely monitoring vaccine safety , effectiveness and optimal use to adapt approaches.

Medcolcanna Announces Postponement of AGM Scheduled for May 19, 2021

Saturday, May 15, 2021 - 12:19am

b'Bogot\xc3\xa1, Colombia--(Newsfile Corp. - May 14, 2021) - Medcolcanna Organics Inc. (TSXV: MCCN) ("Medcolcanna", "MCCN" or the "Company"), a Canadian medical cannabis company with operations in Colombia, announces that its annual general and special meeting of holders of common shares scheduled for Wednesday, May 19, 2021 at 11:00 a.m. (Bogota time) at the offices of the Company will be postponed to a later date, with details of the new date and time to be provided in a future news release.

Key Points: 
  • b'Bogot\xc3\xa1, Colombia--(Newsfile Corp. - May 14, 2021) - Medcolcanna Organics Inc. (TSXV: MCCN) ("Medcolcanna", "MCCN" or the "Company"), a Canadian medical cannabis company with operations in Colombia, announces that its annual general and special meeting of holders of common shares scheduled for Wednesday, May 19, 2021 at 11:00 a.m. (Bogota time) at the offices of the Company will be postponed to a later date, with details of the new date and time to be provided in a future news release.
  • Led by a proven and successful management team, Medcolcanna has facilities in optimal growing locations which positions the Company to become a global leader in the medical cannabis market.\nMedcolcanna employs state of the art organic agricultural technology and innovative pharmaceutical processes to produce high-quality products.
  • Hard work and strong commitment have taken us here and we will relentlessly continue to fulfill our mission to bring high quality cannabis based products at highly competitive prices in order to help improve several medical conditions for patients in need.
  • "\nIf you would like to receive News Releases via email as soon as they are published, please subscribe here: https://medcolcanna.com/contact-us/ or write to info@medcolcanna.com .\n'

Prometheus Biosciences to Present at 2021 RBC Capital Markets Global Healthcare Conference

Friday, May 14, 2021 - 9:01pm

b'SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bowel disease (IBD), today announced that Mark McKenna, President and CEO, will participate virtually in a fireside chat during the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 10:55 a.m. ET.\nPrometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of immune-mediated diseases, starting first with IBD.

Key Points: 
  • b'SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bowel disease (IBD), today announced that Mark McKenna, President and CEO, will participate virtually in a fireside chat during the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 10:55 a.m. ET.\nPrometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of immune-mediated diseases, starting first with IBD.
  • The Company\xe2\x80\x99s\xc2\xa0precision medicine platform, Prometheus360, combines proprietary bioinformatics discovery methods with one of the world\xe2\x80\x99s largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets.\xc2\xa0 Prometheus is headquartered in San Diego, CA.\n'

‘Vaccinate Our World’ Campaign - Europe Press Launch Virtual Press Conference 2-3pm GMT, 18 May 2021

Friday, May 14, 2021 - 10:02pm

\xe2\x80\x9cThe Biden administration took an unprecedented step in supporting a proposal before the WTO to waive intellectual property protections for COVID-19 vaccines during the pandemic.

Key Points: 
  • \xe2\x80\x9cThe Biden administration took an unprecedented step in supporting a proposal before the WTO to waive intellectual property protections for COVID-19 vaccines during the pandemic.
  • If we are to have a real shot at ending the COVID-19 pandemic globally, we urge the UK and EU to follow suit.
  • \xe2\x80\x9cThe \xe2\x80\x98VOW\xe2\x80\x99 call-to-action is about uniting advocates and government leaders worldwide and shining a spotlight on the immorality of vaccine rationing.
  • For more information on the campaign, please visit www.VaccinateOurWorld.org\nAHF Spokespeople and cases studies worldwide available to interview.

Quidel’s QuickVue® At-Home OTC COVID-19 Test Now Available for Sale Through Amazon

Friday, May 14, 2021 - 9:10pm

The QuickVue\xc2\xae At-Home OTC COVID-19 Test has not been FDA cleared or approved.

Key Points: 
  • The QuickVue\xc2\xae At-Home OTC COVID-19 Test has not been FDA cleared or approved.
  • An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S.
  • For more information about Quidel, visit quidel.com .\nThis press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties.
  • You are cautioned not to place undue reliance on these forward-looking statements, which reflect management\xe2\x80\x99s analysis only as of the date of this press release.

ProfNet Expert Alerts for May 14, 2021

Friday, May 14, 2021 - 9:00pm

I help families make sure their home air is clean and free of pollutants and pathogens.

Key Points: 
  • I help families make sure their home air is clean and free of pollutants and pathogens.
  • "\nCaroline can share advice on how to keep homes healthy and virus free - especially during high allergy seasons and under the cloak of the pandemic.
  • Caroline has developed many unique testing methods and products for residential consumers to evaluate their homes and maintain healthy environments economically.
  • She spends substantial time investigating new testing methods and products that will aid her clients with healthier living.

AHN Cancer Institute Becomes One of Nation's First to Use Breakthrough Technology to Advance Radiation Therapy

Friday, May 14, 2021 - 8:00pm

The MR-Linac is located at AHN\'s Cancer Institute hub at Allegheny General Hospital.\n"With the MR-Linac, we are able to offer patients the most sophisticated, effective and personalized radiation therapy possible for their specific diagnosis and tumor characteristics," said David Bartlett, MD , Chair, AHN Cancer Institute.

Key Points: 
  • The MR-Linac is located at AHN\'s Cancer Institute hub at Allegheny General Hospital.\n"With the MR-Linac, we are able to offer patients the most sophisticated, effective and personalized radiation therapy possible for their specific diagnosis and tumor characteristics," said David Bartlett, MD , Chair, AHN Cancer Institute.
  • "Investment in this unique technology is just another example of how we are transforming cancer treatment at AHN.
  • AHN Cancer Institute is a Quality Oncology Practice Initiative certified practice, and is accredited by the Foundation for Accreditation of Cellular Therapy, National Accreditation Program for Breast Centers and the National Accreditation Program for Rectal Cancer.
  • AHN also has a formal affiliation with the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, one of the nation\'s 41 comprehensive cancer centers designated by the National Cancer Institute, for research, medical education and clinical services.\n'

Sciton U.K. Announces Central London Flagship Showroom and Training Centre in Partnership with Skin Group International Ltd (SGI)

Friday, May 14, 2021 - 7:08pm

"Harley Street in London represents an area well known for excellence in medical aesthetics.

Key Points: 
  • "Harley Street in London represents an area well known for excellence in medical aesthetics.
  • Sciton offers aesthetic and medical devices for women\'s health, fractional and full-coverage skin resurfacing and skin revitalization, phototherapy, vascular and pigmentation lesions, scar reduction, acne, body contouring, and hair reduction.
  • Sciton operates on a worldwide basis with direct sales teams in the United States, Canada, Australia, United Kingdom, Ireland, Japan and distributor partners in more than 45 countries.
  • For more information, and a complete listing of Sciton systems, visit www.sciton.com .\n'

Global Joint Pain Injection Market (2021 to 2028) - COVID-19 Impact and Analysis - ResearchAndMarkets.com

Friday, May 14, 2021 - 5:38pm

However, the high costs of joint repair therapies hinder the market growth.\nHyaluronic acid injections are usually administered for treating sports injuries, as they aid in pain relief, reduce inflammation, and improve joint function.

Key Points: 
  • However, the high costs of joint repair therapies hinder the market growth.\nHyaluronic acid injections are usually administered for treating sports injuries, as they aid in pain relief, reduce inflammation, and improve joint function.
  • Sports injuries are caused due to direct impact or due to the application of force that is larger than the body part can withstand.
  • Thus, the growing number of sport injuries is boosting the demand for joint pain injections.\nBased on joint type, the joint pain injection market is segmented into knee, shoulder and elbow, hip, foot and ankle, and others.
  • In 2020, the knee joint type segment accounted for the largest share of the market.

Veracyte Announces Data Showing Percepta Genomic Atlas Detects Gene Alterations Targeted in Lung Cancer Treatment, Using Diagnostic Biopsy

Friday, May 14, 2021 - 5:45pm

(Nasdaq: VCYT) announced today new data demonstrating the ability of the Percepta\xc2\xae Genomic Atlas to detect alterations that may inform lung cancer treatment decisions for patients from the same small biopsy that was used for diagnosis.

Key Points: 
  • (Nasdaq: VCYT) announced today new data demonstrating the ability of the Percepta\xc2\xae Genomic Atlas to detect alterations that may inform lung cancer treatment decisions for patients from the same small biopsy that was used for diagnosis.
  • The test uses targeted DNA and whole-transcriptome RNA sequencing to detect alterations in more than 50 genes known to be present in lung cancer.
  • The company\xe2\x80\x99s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development.
  • Examples of forward-looking statements include, among others, statements regarding the ability of the Percepta Genomic Atlas to accurately detect known lung-cancer gene variants and help to guide treatment with targeted therapies.